← Back to Screener
Inhibikase Therapeutics, Inc. Common Stock (IKT)
Price$1.81
Favorite Metrics
Price vs S&P 500 (26W)4.92%
Price vs S&P 500 (4W)-7.83%
Market Capitalization$241.62M
All Metrics
Book Value / Share (Quarterly)$1.31
P/TBV (Annual)0.26x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.21
Price vs S&P 500 (YTD)-14.87%
Net Profit Margin (TTM)-5981.25%
EPS (TTM)$-1.15
10-Day Avg Trading Volume0.99M
EPS Excl Extra (TTM)$-1.15
EPS (Annual)$-1.16
ROI (Annual)-29.01%
Net Profit Margin (5Y Avg)-4748.27%
Cash / Share (Quarterly)$1.36
ROA (Last FY)-27.91%
EBITD / Share (TTM)$-0.71
ROE (5Y Avg)-71.16%
Operating Margin (TTM)-6253.12%
Cash Flow / Share (Annual)$-0.21
P/B Ratio1.40x
P/B Ratio (Quarterly)1.44x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)320.00x
Net Interest Coverage (TTM)-738.50x
ROA (TTM)-52.76%
EPS Incl Extra (Annual)$-1.16
Current Ratio (Annual)21.70x
Quick Ratio (Quarterly)21.54x
3-Month Avg Trading Volume1.51M
52-Week Price Return-7.58%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.80
P/S Ratio (Annual)927.52x
Asset Turnover (Annual)0.02x
52-Week High$2.37
Operating Margin (5Y Avg)-4841.72%
EPS Excl Extra (Annual)$-1.16
26-Week Price Return13.66%
Quick Ratio (Annual)21.54x
13-Week Price Return7.65%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)21.70x
Enterprise Value$102.4
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-25.76%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-7304.75%
Cash / Share (Annual)$1.36
3-Month Return Std Dev65.21%
Net Income / Employee (TTM)$-3
ROE (Last FY)-29.01%
Net Interest Coverage (Annual)-178.00x
EPS Basic Excl Extra (Annual)$-1.16
P/FCF (TTM)3020.25x
Receivables Turnover (TTM)6.67x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.15
Receivables Turnover (Annual)13.03x
ROI (TTM)-57.15%
P/S Ratio (TTM)755.06x
Pretax Margin (5Y Avg)-4748.27%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.00
Price vs S&P 500 (52W)-42.67%
Year-to-Date Return-10.73%
5-Day Price Return7.02%
EPS Normalized (Annual)$-1.16
ROA (5Y Avg)-57.11%
Net Profit Margin (Annual)-7304.75%
Month-to-Date Return8.93%
Cash Flow / Share (TTM)$-3.92
EBITD / Share (Annual)$-1.20
Operating Margin (Annual)-7712.01%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-70.92%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.15
P/TBV (Quarterly)0.36x
P/B Ratio (Annual)1.44x
Pretax Margin (TTM)-5981.25%
Book Value / Share (Annual)$1.31
Price vs S&P 500 (13W)4.78%
Beta0.97x
P/FCF (Annual)340.31x
Revenue / Share (TTM)$0.00
ROE (TTM)-57.15%
52-Week Low$1.33
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.18
4.18
4.25
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IKTInhibikase Therapeutics, Inc. Common Stock | 755.06x | — | — | — | $1.81 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing selective protein kinase inhibitors for neurological disorders. Its lead program, Risvodetinib (IkT-148009), targets Parkinson's disease and related conditions driven by Abelson Tyrosine Kinase dysfunction. The company focuses on disease-modifying therapies for Parkinson's and other neurodegenerative conditions.